Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

und RG7227 (ITMN-191) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently has submitted in support of its NDA file and plans to submit in support of its MAA filing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly fol
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... Novel Biomarkers Displaying 90% Sensitivity in Breast ... ... announced today the,discovery and validation of the most frequent DNA alterations detected ... appeared in PLoS ONE. The study entitled, "Identification of,Novel High-Frequency DNA Methylation ...
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based ... has retained Financial,Relations Board (FRB), as its Investor ... HIV-1/AIDS vaccine human trial results need to be,conveyed ... AIDS,pandemic," stated Kathy Waller, co-president of FRB., ...
Cached Medicine Technology:Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 3GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 4
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... FL (PRWEB) May 22, 2015 Wimbledon ... provides vascular, electrocardiogram (EKG), echocardiogram and NCV testing ... Sempier, a highly respected All American National athlete, to ... athlete, I find the high level of testing and ... the athlete and their athletic trainers, this way they ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened ... years they have concentrated their focus to working with ... Because of this growth and their goals to better ... Denver, Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, ... dental offices, dental start ups, orthodontic practices, pediatric dental ...
(Date:5/22/2015)... In efforts to offer full and robust resources ... stretches has been a large focus over the last ... Chunk Fitness envisions a mid-June launch of these resources. ... at a later point in time. The current resources ... , About the Company: Chunk Fitness was founded in ...
(Date:5/21/2015)... York (PRWEB) May 21, 2015 World ... patented products, launches the Troll Motor Guide, a boat ... of boating. , "The recreational boating industry has reached ... Cooper, CEO and Creative Director of World Patent ... record numbers and predicts continued steady growth of seven ...
Breaking Medicine News(10 mins):Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... Deployed in "A Strategy of Home Telehealth for the Management ... ... Minneapolis (PRWEB) October 28, 2008 -- American TeleCare, Inc. ... monitoring and video-based telehealth solutions, announced that its InLife™ and ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading ... Earl R. Lewis to the Company,s,Board of Directors and ... "I first want to thank Pete for the ... greatly from working closely with him over the,last 10 ...
... American Society of Plastic Surgeons Annual Meeting, ... Ariz. resident, Iraq War hero and motivational speaker ... recipient of the 2008 Patients of,Courage: Triumph Over ... (ASPS) Plastic Surgery 2008 conference, Saturday, November 1, ...
... American Society of Plastic Surgeons Annual Meeting, ... Louis,native, two-time breast cancer survivor and humanitarian whose ... research, will be the,proud recipient of the 2008 ... American Society of Plastic Surgeons (ASPS) Plastic Surgery,2008 ...
... Modified Smoking Cessation Strategy Needed, PHILADELPHIA, ... a,15-year high, with nearly 75 percent of ... nicotine dependent. New,research, presented at CHEST 2008, ... American College of Chest Physicians (ACCP), reports ...
... Americans curtail spending to,offset economic challenges, they,re placing ... to provide an invaluable service despite,the shaky consumer ... program for new moms found in over 800 ... clients," explains Rachel Pustilnik, owner,of the Richmond, VA ...
Cached Medicine News:Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 2Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 3Health News:Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada 4Health News:NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member 2Health News:NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member 3Health News:Gilbert Resident, Iraq War Hero Wins Patient of Courage Award 2Health News:St. Louis Local, Two-Time Breast Cancer Survivor Receives Courage Award 2Health News:US Nicotine Addiction Reaches 15-Year High 2Health News:US Nicotine Addiction Reaches 15-Year High 3Health News:Stroller Strides(R) Franchises Succeed Despite Economic Climate 2
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
Molteno3 Glaucoma Drainage Device incorporates the latest advances from Professor Moltenos glaucoma research. It has been extensively tested since early 2004 and gives even better control of intraocu...
... reagent and probe system used together to ... plate based system is a sandwich nucleic ... approach for RNA detection and quantification, by ... (bDNA) technology. Branched DNA allows immediate quantification ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
Medicine Products: